Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3987538 | European Journal of Surgical Oncology (EJSO) | 2010 | 7 Pages |
Abstract
The study showed that peptidomics technology is able to identify possible biomarkers of neoplastic CNS disease. It remains to be determined if the identified elevated CSF peptides are specific for GBM. With regard to GBM, however, the more important role of CSF peptide biomarkers than aiding initial diagnosis might be early recognition of disease recurrence or monitoring of efficacy of adjuvant therapy protocols.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M.U. Schuhmann, H.D. Zucht, R. Nassimi, G. Heine, C.G. Schneekloth, H.J. Stuerenburg, H. Selle,